Saratov JOURNAL of Medical and Scientific Research

Platelet functional pools under pharmacological suppression of aggregation in ST segment elevation myocardial infarction

Year: 2019, volume 15 Issue: №3 Pages: 779-783
Heading: Cardiology Article type: Original article
Authors: Malinova L.I., Dolotovskaya P.V., Furman N.V., Puchinyan N.F., Lipatova Т.Е.
Organization: Saratov State Medical University

The purpose of the study is to investigate clinical significance of peripheral pool platelets functional heterogeneity, assessed with combination of collagen and ADP, under pharmacological suppression of platelet aggregation in acute coronary syndrome. Material and Methods. The study involved 374 patients with acute coronary syndrome (ACS). Functional activity of platelets (FAT) was studied on the first, the 7th and 30th days after ACS manifestation in the whole blood by impedance and luminescent aggregometry. The functional heterogeneity of platelets was studied using our own method with an estimate of AAk (functional subpopulation of platelets aggregation (cluster II)), ASk (the functional subpopulation of platelets secretion (cluster II)) and ДА (a parameter of platelets functional heterogeneity). The follow-up period was 24 months after ACS manifestation. Results. In the study sample ADP- and collagen-induced platelet aggregation remained almost constant during the whole observation period. It was established that in patients treated with double antiplatelet therapy parameters of functional platelet heterogeneity statistically significantly decreased by the seventh day of observation: ЛАк 2(0; 3)vs 1 (0; 2) Ohm, p=0,049; AS 0.26 (0.15; 0.47) vs 0.19 (0; 0.26) nmol, p=0.07. The excess of ЛАР measured on the second day after ACS manifestation, a threshold of 2 Ohms, was associated with a significant increase in the 30-day risk of rethrombotic events (HR 1.8; Cl 1.2; 3.1). Conclusion. The dynamics of platelet functional heterogeneity was revealed in patients with acute coronary syndrome treated with double antiplatelet therapy. A high degree of platelet functional heterogeneity in patients with acute coronary syndrome was associated with a significant increase in the 30-day risk of rethrombotic events.

1 NurdenAT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl 1): S13-33.
2 Szasz R, Dale GL. COAT platelets. Curr Opin Hematol 2003; 10:351-5.
3 Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des2012; 18: 5344-61.
4 Behnke O, Forer A. Blood platelet heterogeneity: evidence for two classes of platelets in man and rat. Br J Haematol 1993; 84: 686-93.
5 Behnke O. Blood platelet heterogeneity: a functional hierarchy in the platelet population. Br J Haematol 1995; 91: 991-9.
6 Alberio L, Safa O, Clemetson KJ, et al. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000; 95: 1694-702.
7 Vu TK, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
8 Alekyan BG, Abugov SA, Andreev DA, et al. The role of platelet functional activity testing in the prevention of cardiovascular complications in patients receiving antiplatelet therapy. Rational Pharmacotherapy in Cardiology 2014; 10: 679-87.
9 A method for determining platelet aggregation activity in patients with acute coronary syndrome: Patent for invention RU 2619858 C1/Malinova LI, Dolotovskaya PV, Furman NV In: Inventions. Utility Models: Official Bulletin of the Federal Service for Intellectual Property, Patents and Trademarks. Moscow, 2017
10 Dale GL, Friese Р, Batar Р, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002; 415: 175-9.
11 Bertaggia Calderara D, Crettaz D, Aliotta A, et al. Generation of procoagulant collagen- and thrombin-activated platelets in platelet concentrates derived from buffy coat: the role of processing, pathogen inactivation, and storage. Transfusion 2018;58:2395-406.
12 Alberio LJ, Clemetson KJ. All platelets are not equal: COAT platelets. Current hematology reports 2004; 3: 338- 43
13 Barbarash OL, Kashtalap VV Duration of dual antiplatelet therapy: Facts and Assumptions. Russian Journal of Cardiology 2016; 130: 75-83.

2019_03-1_779-783.pdf562.29 KB

No votes yet